Sanford Laboratories for Innovative Medicines

What Sanford Laboratories for Innovative Medicines does

Sanford Laboratories for Innovative Medicines (Sanford Labs) is an independent not-for-profit biomedical research organization founded in July 2023 and headquartered at 3535 General Atomics Court in San Diego, California. It operates a collaborative hub model designed to fill the translational gap between academic labs and venture-backed biotech, running parallel research programs organized around therapeutic approaches and platform technologies rather than single-asset development.

Its scientific focus is next-generation RNA therapeutics, spanning antisense oligonucleotides (ASO), mRNA translation enhancement, small molecule RNA degraders, catalytic RNA therapeutics, RNA aptamers, and RNA-binding protein targeting platforms. Active programs include Project Saguaro (addressing TDP-43 dysfunction in ALS and frontotemporal dementia), an oligonucleotide-based protein expression platform for haploinsufficiency disorders, small molecule RNA degradation for gain-of-function disease, and an RNA-binding protein platform for neurodegenerative diseases. The organization layers proprietary AI/ML pipelines (RNA language models, generative chemistry, multi-omics integration) across these platforms, with in-house ML leadership and bioinformatics scientists supporting target identification and therapeutic candidate generation.

Sanford Labs does not sell products commercially. Revenue mechanics are philanthropic (T. Denny Sanford philanthropy), potential licensing and partnership income at proof-of-concept, government grants, and spinout company generation. The primary "customer" segments are entrepreneurial scientists (both internally and externally) seeking a translational platform with industry-grade rigor, biopharma companies for licensing/acquisition of de-risked programs at proof-of-concept, and strategic/financial partners. Scientific advisory and ecosystem relationships include UC San Diego (Venture Fellows Program), Sanford Burnham Prebys, Sanford Consortium for Regenerative Medicine, and Sanford Health, anchoring the organization within the San Diego life science cluster.

Name

Sanford Laboratories for Innovative Medicines

Legal name

Sanford Laboratories for Innovative Medicines

Website

https://sanfordlabs.org

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Sanford Labs is an independent not-for-profit biomedical research organization, founded in San Diego in July 2023, that runs multiple parallel RNA therapeutics programs — including antisense oligonucleotides, small molecule RNA degraders, and RNA-binding protein targeting — aimed at diseases such as ALS and pediatric genetic epilepsies, with funding primarily from T. Denny Sanford philanthropy and a go-to-market model based on biopharma licensing and spinout generation.

Ownership category

akta.pro rank

Product category

RNA Therapeutics Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• RNA therapeutics research
• Antisense oligonucleotide development
• Translational biomedical research
• Small molecule RNA degraders
• Biopharma research collaboration

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Philanthropic Funding: Sanford Labs operates as an independent not-for-profit research organization. The organization benefits from private funding through philanthropy, enabling programs to launch without incremental grants or external capital. T. Denny Sanford has donated more than $2 billion to various causes and is a strong champion for biomedical research.
2. Licensing and Partnerships: Programs demonstrating proof-of-concept are expected to provide opportunities for start-up company generation and biopharma partnering. Long-term sustainability through academic, philanthropic, industry and government agency partnerships and spinout companies.
3. Government Grants: As a not-for-profit biomedical research organization, Sanford Labs operates under Financial Conflict of Interest Policy per Title 42 CFR 50, Subpart F for PHS-funded research.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sanford Laboratories for Innovative Medicines is an independent not-for-profit research organization that advances next-generation RNA therapeutics through internal research programs organized around platform technologies. Programs span antisense oligonucleotides for haploinsufficiency and pediatric genetic epilepsies, small molecule RNA degraders, catalytic RNA therapeutics, RNA aptamers, RNA-binding protein targeting for neurodegenerative disorders, and AI/ML-enabled drug discovery. Mature programs with proof-of-concept data are advanced toward biopharma licensing, spinout formation, and academic partnerships.

Product overview

Sanford Laboratories for Innovative Medicines is an independent not-for-profit research organization pioneering a new model for biomedical research focused on RNA therapeutics. The company operates therapeutic programs organized around platform technologies including: Project Saguaro (targeting ALS/FTD through TDP-43 dysfunction), an oligonucleotide-based protein expression platform for haploinsufficiency disorders, a small molecule RNA degradation platform, and an RNA-binding protein targeting platform for neurodegenerative diseases. Research programs are led by entrepreneurial scientists organized around therapeutic approaches and platform technologies with broad applicability to multiple diseases, enabling efficient prototyping of multiple new medicines in parallel.

Differentiator

Problem solved

Functional benefit

Products and services

• Project Saguaro A therapeutic research program developing treatments for ALS and frontotemporal dementia by addressing TDP-43 dysfunction through antisense oligonucleotide and small molecule approaches, currently advancing toward biopharma partnership.
• Oligonucleotide-Based Protein Expression Platform A research platform developing bifunctional small molecules and antisense oligonucleotide approaches to increase protein expression levels, targeting haploinsufficiency disorders where loss of a single gene copy produces disease.
• Small Molecule RNA Degradation Platform A research platform identifying and developing small molecules that degrade or inhibit specific RNA molecules to treat diseases where excess or pathogenic versions of proteins drive pathology.
• RNA-Binding Protein (RBP) Targeting Platform A research platform focused on targeting RNA-binding proteins as therapeutic targets for neurodegenerative disorders and other diseases with high unmet medical need, leveraging understanding of mRNA-RBP interactions.
• Antisense Oligonucleotide Pediatric Epilepsy Program A splice-switching antisense oligonucleotide research program for pediatric genetic epilepsies.

Quantifiable outcome

• 25+ RNA therapies and vaccines already approved to date with hundreds more in development pipeline
• +1 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• UC San Diego (Sullivan Center for Entrepreneurship and Innovation)coreStrategic or Co-development Partner · 30 October 2023Venture Fellows Program partnership where interdisciplinary teams of students from UC San Diego's Rady School of Management work directly with scientific founders to support deep market analysis, business plan development, and assessment of commercialization pathways for novel research. Eight fellows performed market analysis including competitive landscape review, target product profile, and primary source interviews for one of Sanford Labs' prototype RNA-based drugs.
• Sanford Burnham Prebys Medical Discovery InstitutecoreStrategic or Co-development PartnerCollaborations underway with Sanford Burnham Prebys Medical Discovery Institute in San Diego. Feedback from SBP's Conrad Prebys Center for Chemical Genomics has been valuable for small molecule discovery efforts. Scientists support research programs through shared resources and expertise.
• Sanford HealthminorStrategic or Co-development PartnerScientists at South Dakota-based Sanford Health have provided expert insights on how to tackle rare children's diseases with unmet medical need.
• Sanford Consortium for Regenerative MedicinecoreStrategic or Co-development PartnerEdward Holmes is President and CEO of the Sanford Consortium for Regenerative Medicine and Chair of Sanford Labs' board. The RNA and AI Symposium was held at the Roth Auditorium at the Sanford Consortium for Regenerative Medicine. The Consortium provides venue and organizational support.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Emerging players

• ProQR Therapeutics: Clinical-stage RNA editing therapeutics company focused on rare diseases. Comparable as an emerging player in RNA-targeted therapeutics for genetic disorders, with similar therapeutic area overlap to Sanford Labs' haploinsufficiency and rare genetic disease programs.
• Atomic AI: AI-driven RNA structure prediction and RNA-targeted drug discovery company. Comparable as an emerging player applying AI/ML to RNA therapeutics, directly relevant to Sanford Labs' AI/ML-for-RNA capability; Sanford Labs Chief Scientist Gene Yeo is a scientific advisor to Atomic AI.
• Orbital Therapeutics: RNA therapeutics company developing novel RNA modalities including circular RNA. Comparable as an emerging RNA therapeutics player; Sanford Labs Chief Scientist Gene Yeo is a scientific advisor to Orbital Therapeutics, suggesting strategic alignment with Sanford Labs' RNA therapeutics focus.

Direct peers

• Arcturus Therapeutics: Clinical-stage RNA therapeutics company developing mRNA, siRNA, and ASO modalities. Directly comparable as RNA therapeutics peer; Board Chair Edward Holmes of Sanford Labs is also a board member of Arcturus, providing direct governance overlap and indicating a similar San Diego-based RNA therapeutics focus area.
• Eclipsebio: RNA biology tools and RNA-RBP mapping company. Highly comparable: Sanford Labs' Chief Scientist Gene Yeo co-founded multiple RNA biotech ventures, multiple Sanford Labs staff scientists (Dan Lorenz, Maya Kunkel, Jasmine Mueller) previously worked at Eclipsebio, and the organizations share overlapping focus on RNA-targeting platforms and RNA-RBP interactions.
• Trotana Therapeutics: RNA-binding protein-targeted therapeutics for neuroscience. Directly comparable: co-founded by Sanford Labs' Group Leader Sebastian Markmiller, who raised $18M+ in seed funding; multiple Sanford Labs staff (Markmiller, Luna, Novotna, Vukovic, Jin) previously held roles at Trotana. Both focus on RBP targeting for neurodegenerative diseases.

Broad incumbents

• Alnylam Pharmaceuticals: The leading commercial siRNA therapeutics company with multiple approved products. Broadly comparable as the dominant incumbent in RNA therapeutics, including RNA-targeting approaches that overlap with Sanford Labs' small molecule RNA degrader and ASO platforms; represents the type of biopharma partner Sanford Labs would target.
• Ionis Pharmaceuticals: Pioneer in antisense oligonucleotide (ASO) therapeutics with deep clinical pipeline. Broadly comparable as the established leader in ASO modality — directly relevant to Sanford Labs' antisense oligonucleotide programs for haploinsufficiency disorders and Project Saguaro. Represents another potential biopharma partner category.
• Moderna: Major mRNA therapeutics and vaccines company. Broadly comparable as the dominant commercial player in mRNA therapeutics — directly relevant to Sanford Labs' core mRNA focus area, including mRNA as vaccine/therapy and mRNA translation enhancement platforms.
• Sarepta Therapeutics: RNA-targeted therapeutics company focused on rare diseases, particularly antisense oligonucleotide and gene therapy approaches. Broadly comparable as a commercial-stage antisense/RNA therapeutics player; Sanford Labs' ML scientist Deevanshu Goyal previously worked at Sarepta on CRISPR/Cas9 ML model development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sanford-laboratories-for-innovative-medicines
• Xx.com/sanford_labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanford Laboratories for Innovative Medicines